Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3–5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or neurorestorative treatments. Due to their spectrum of capaci...
Main Authors: | Flore Gouel, Anne-Sophie Rolland, Jean-Christophe Devedjian, Thierry Burnouf, David Devos |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-08-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2019.00835/full |
Similar Items
-
Extensive characterization of the composition and functional activities of five preparations of human platelet lysates for dedicated clinical uses
by: Liling Delila, et al.
Published: (2021-02-01) -
Heat-treated human platelet pellet lysate modulates microglia activation, favors wound healing and promotes neuronal differentiation in vitro
by: Ouada Nebie, et al.
Published: (2021-02-01) -
Human platelet lysates for human cell propagation
by: Lassina Barro, et al.
Published: (2021-02-01) -
The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates
by: Ouada Nebie, et al.
Published: (2019-10-01) -
Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery
by: Thierry Burnouf, et al.
Published: (2023-09-01)